Skip to main content
Guangzhou Innogen Pharmaceutical Group Co., Ltd. logo

Guangzhou Innogen Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 2591 HKEX Manufacturing
Open in API
Filings indexed 45 across all filing types
Latest filing 2026-04-28 Environmental & Social …
Country HK Hong Kong
Listing HKEX 2591

About Guangzhou Innogen Pharmaceutical Group Co., Ltd.

https://www.innogenpharm.com

Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a science-driven company focused on the discovery, development, and commercialization of innovative therapies for metabolic diseases. The company targets high-prevalence conditions including diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH), alongside central nervous system disorders. Its primary product, Supaglutide alpha, is a humanized long-acting GLP-1 receptor agonist developed to provide effective treatment for diabetes. Innogen utilizes a proprietary recombinant protein biological drug technology platform to maintain a self-developed pipeline with global intellectual property rights. The organization is led by a team of specialists with extensive experience in metabolic research, aiming to deliver accessible and high-quality therapeutic solutions to global markets.

Recent filings

Filing Released Lang Actions
Environmental, Social and Governance Report 2025
Environmental & Social Information Classification · 1% confidence The document is a comprehensive Environmental, Social and Governance (ESG) Report for the year 2025, published by Guangzhou Innogen Pharmaceutical Group Co., Ltd. It includes detailed sections on environmental performance (emissions, resource usage, climate change), social aspects (employment, health & safety, supply chain management, anti-corruption, community investment), governance statements, materiality assessment, and several appendices (ESG KPIs, HKEX ESG Reporting Code index, climate-related disclosures index). It is clearly the full ESG report itself rather than a brief announcement or template. This matches our Filing Definitions for Environmental & Social Information (Code: SR).
2026-04-28 English
Annual Report 2025
Regulatory Filings
2026-04-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a Monthly Return (Form FF301) filed by a Hong Kong–listed issuer under the Exchange Listing Rules, detailing routine movements in authorised/issued share capital and public float confirmation for the month. It is a regulatory compliance filing rather than an earnings release, capital raising announcement, or actual share issuance. It does not announce a dividend or legal proceeding. Therefore, it best fits the fallback category for general regulatory announcements: Regulatory Filings (RNS).
2026-04-08 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is titled “Annual Results Announcement for the Year Ended 31 December 2025” and contains summary financials (consolidated income statement and balance sheet key figures) along with Management Discussion and Analysis (MD&A). This matches the structure of an earnings release—the initial announcement of periodical financial results with key highlights—rather than a full annual report. Therefore, it should be classified as an Earnings Release. FY 2025
2026-03-23 English
CHANGE OF JOINT COMPANY SECRETARY; AGENT FOR SERVICE OF PROCESS AND AUTHORISED REPRESENTATIVE; AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 1% confidence The document is a corporate announcement from the Board of Guangzhou Innogen Pharmaceutical Group regarding the resignation and appointment of key company secretarial personnel (joint company secretary, agent for service of process, authorised representative) and a waiver under Listing Rules. This is an announcement of changes in senior management and company officers, fitting the Board/Management Information category.
2026-03-23 English
INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION
Share Issue/Capital Change Classification · 1% confidence The document is an announcement regarding the 'Proposed Implementation of the H Share Full Circulation' by Guangzhou Innogen Pharmaceutical Group Co., Ltd. It details the company's application to the CSRC for converting domestic unlisted shares into H shares. This relates to capital structure and share listing status, which falls under the category of capital changes or financing updates. Since it specifically addresses the conversion of shares and listing status, 'SHA' (Share Issue/Capital Change) is the most appropriate classification.
2026-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.